Exelixis and Merck Join Forces to Develop Zanzalintinib for Head and Neck Cancer and Renal Cell Carcinoma
Shots:
- Exelixis has signed a clinical development agreement with Merck to develop its zanzalintinib plus Keytruda for treating PD-L1+ recurrent or metastatic HNSCC (currently in P-III) & Welireg for treating RCC (currently in P-I/II & two P-III studies)
- As per the agreement, Merck will provide Keytruda for P-III (STELLAR-305) study of HNSCC (sponsored by Exelis), sponsor all the studies in RCC & will fund one of the P-III studies. Exelixis will co-fund P-I/II & other P-III trial, supply zanzalintinib & cabozantinib, while retaining worldwide commercial rights to zanzalintinib
- Zanzalintinib is a tyrosine kinase inhibitor, involved in various cancer-related pathways inhibition associated with resistance to immune checkpoint inhibitors
Ref: Merck | Image: Merck and Exelixis
Related News:- Merck Provides Update on P-III (KEYNOTE-689) Study of Keytruda as a Perioperative Treatment of Head and Neck Squamous Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
